Elevance Health (ELV) Cash & Equivalents (2009 - 2026)

Elevance Health (ELV) has 18 years of Cash & Equivalents data on file, last reported at $9.7 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $9.7 billion, up 28.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.7 billion (up 28.76% YoY), and the FY2025 annual result was $9.5 billion, up 14.51% from the prior year.
• Cash & Equivalents climbed to $9.7 billion in Q1 2026 per ELV's latest filing, from $9.5 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $10.9 billion in Q3 2023 and troughed at $6.2 billion in Q1 2022.
• A 5-year average of $8.2 billion and a median of $8.3 billion in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 64.62% in 2023, then plunged 38.61% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $7.4 billion in 2022, then slipped by 11.66% to $6.5 billion in 2023, then increased by 27.0% to $8.3 billion in 2024, then climbed by 14.51% to $9.5 billion in 2025, then grew by 1.75% to $9.7 billion in 2026.
• Business Quant data shows ELV's Cash & Equivalents at $9.7 billion in Q1 2026, $9.5 billion in Q4 2025, and $8.7 billion in Q3 2025.